Purification and Autoactivation Method for Recombinant Coagulation Factor VII
Recombinant coagulation factor VII is a very important and complex protein employed for treatment of hemophiliac patients (hemophilia A/B) who develop inhibitors antibodies to conventional treatments (FVIII and FIX). The rFVII is a glycosylated molecule and circulates in plasma as zymogen of 50 kDa. When activated the molecule is cleaved to 20–30 kDa and has a half-life of about 3 h, needing to be processed fast and efficiently until freeze-drying. Here, we describe a very simple and fast purification sequence for rFVII using affinity FVII Select resin and a dialysis system that can be easily scaled up.
Key wordsRecombinant coagulation factor VII Affinity chromatography FVII autoactivation rFVII purification methodology
- 5.Bharadwaj D, Iino M, Kontoyianni M, Smith KJ, Foster DC, Kisiel W (1996) Factor VII central. A novel mutation in the catalytic domain that reduces tissue factor binding, impairs activation by factor Xa, and abolishes amidolytic and coagulant activity. J Biol Chem 271(48):30685–30691CrossRefPubMedGoogle Scholar
- 8.Covas DT, Freitas MCC, Picanço-Castro V, Swiech K (2015) Processo de Produção de Fator VII de coagulação sanguínea e fator VII de coagulação sanguínea. Instituto Nacional da Propriedade Industrial (INPI) BR1020150123345Google Scholar